BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38733180)

  • 1. [Current status and challenges of clinical research and development of new drugs for liver diseases].
    Shen ZY; Cai XB; Lu LG
    Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):289-294. PubMed ID: 38733180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Clinical Trials of New Drugs for Liver Diseases in China.
    Lin L; Li H
    Drug Des Devel Ther; 2021; 15():3181-3191. PubMed ID: 34321867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status in the therapy of liver diseases.
    Uhl P; Fricker G; Haberkorn U; Mier W
    Int J Mol Sci; 2014 Apr; 15(5):7500-12. PubMed ID: 24786290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A report from The Liver Meeting 2014 (November 7-11 - Boston, Massachusetts, USA).
    Rabasseda X
    Drugs Today (Barc); 2014 Nov; 50(11):763-74. PubMed ID: 25525637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Challenges and optimization strategies for clinical research and the development of new drugs for liver fibrosis].
    Cai XB; Qu Y; Lu LG
    Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):303-305. PubMed ID: 38733183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases.
    Mallat A; Teixeira-Clerc F; Deveaux V; Lotersztajn S
    Expert Opin Ther Targets; 2007 Mar; 11(3):403-9. PubMed ID: 17298297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A report from the European Association for the Study of the Liver's 50th International Liver Congress (April 22-26 - Vienna, Austria).
    Rabasseda X
    Drugs Today (Barc); 2015 Apr; 51(4):261-71. PubMed ID: 26020068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Silymarin in the treatment of chronic liver diseases: past and future].
    Fehér J; Lengyel G
    Orv Hetil; 2008 Dec; 149(51):2413-8. PubMed ID: 19073452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albumin-drug conjugates in the treatment of hepatic disorders.
    Fiume L; Manerba M; Di Stefano G
    Expert Opin Drug Deliv; 2014 Aug; 11(8):1203-17. PubMed ID: 24773257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects.
    Vargas JI; Arrese M; Shah VH; Arab JP
    Curr Gastroenterol Rep; 2017 Sep; 19(9):43. PubMed ID: 28752475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Wnt signaling pathway: the challenge of reducing scarring without affecting repair.
    Jarman EJ; Boulter L
    Expert Opin Investig Drugs; 2020 Feb; 29(2):179-190. PubMed ID: 31948298
    [No Abstract]   [Full Text] [Related]  

  • 12. Insight into the role of TRAIL in liver diseases.
    Jiang W; Wu DB; Fu SY; Chen EQ; Tang H; Zhou TY
    Biomed Pharmacother; 2019 Feb; 110():641-645. PubMed ID: 30544063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term therapy of liver diseases].
    Markoff N
    Wien Med Wochenschr; 1972 Feb; 122(7):95-9. PubMed ID: 4621921
    [No Abstract]   [Full Text] [Related]  

  • 14. New Therapies, Evidence, and Guidance in Hepatitis C Management: Expert Practices and Insights from an Educational Symposium at the AMCP 27th Annual Meeting Expo.
    Terrault N; Monto A; Stinchon MR; Rusie E; Moreo K
    J Manag Care Spec Pharm; 2015 Sep; 21(9):S1-14. PubMed ID: 26308363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.
    Janczewska E; Kołek MF; Lorenc B; Klapaczyński J; Tudrujek-Zdunek M; Sitko M; Mazur W; Zarębska-Michaluk D; Buczyńska I; Dybowska D; Czauż-Andrzejuk A; Berak H; Krygier R; Jaroszewicz J; Citko J; Piekarska A; Dobracka B; Socha Ł; Deroń Z; Laurans Ł; Białkowska-Warzecha J; Tronina O; Adamek B; Tomasiewicz K; Simon K; Pawłowska M; Halota W; Flisiak R
    World J Gastroenterol; 2021 May; 27(18):2177-2192. PubMed ID: 34025072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress in diagnosis and treatment of viral hepatitis in children].
    Chang YN; Xu HM
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jan; 29(1):16-20. PubMed ID: 33541019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of Andrographolide in the prevention and treatment of liver diseases.
    Qin X; Wang X; Tian M; Dong Z; Wang J; Wang C; Huang Q
    Phytomedicine; 2023 Jan; 109():154537. PubMed ID: 36610122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How effective are nonalcoholic fatty liver disease models for drug discovery?
    Hundertmark J; Tacke F
    Expert Opin Drug Discov; 2020 Nov; 15(11):1237-1240. PubMed ID: 32524859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs for complications of end-stage liver disease.
    Dowman JK; Holt AP; Newsome PN; Adams DH
    Expert Opin Emerg Drugs; 2008 Mar; 13(1):159-74. PubMed ID: 18321155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential drug delivery for liver diseases.
    Huang X; Lee F; Teng Y; Lingam CB; Chen Z; Sun M; Song Z; Balachander GM; Leo HL; Guo Q; Shah I; Yu H
    Adv Drug Deliv Rev; 2019; 149-150():72-84. PubMed ID: 31734169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.